Author:
Verderosa Anthony D.,Dhouib Rabeb,Hong Yaoqin,Anderson Taylah K.,Heras Begoña,Totsika Makrina
Abstract
AbstractAntibiotics are failing fast, and the development pipeline remains alarmingly dry. New drug research and development is being urged by world health officials, with new antibacterials against multidrug-resistant Gram-negative pathogens as the highest priority. Antivirulence drugs, which inhibit bacterial pathogenicity factors, are a class of promising antibacterials, however, their development is stifled by lack of standardised preclinical testing akin to what guides antibiotic development. The lack of established target-specific microbiological assays amenable to high-throughput, often means that cell-based testing of virulence inhibitors is absent from the discovery (hit-to-lead) phase, only to be employed at later-stages of lead optimization. Here, we address this by establishing a pipeline of bacterial cell-based assays developed for the identification and early preclinical evaluation of DsbA inhibitors, previously identified by biophysical and biochemical assays. Inhibitors of DsbA block oxidative protein folding required for virulence factor folding in pathogens. Here we use existing Escherichia coli DsbA inhibitors and uropathogenic E. coli (UPEC) as a model pathogen, to demonstrate that the combination of a cell-based sulfotransferase assay and a motility assay (both DsbA reporter assays), modified for a higher throughput format, can provide a robust and target-specific platform for the identification and evaluation of DsbA inhibitors.
Funder
National Health and Medical Research Council
Ramaciotti Foundations
Australian Research Council
Queensland University of Technology
Publisher
Springer Science and Business Media LLC
Reference68 articles.
1. World Health Organization. Antimicrobial resistance: Global report on surveillance. (2014). https://apps.who.int/iris/handle/10665/112642.
2. World Health Organization. Antibacterial agents in clinical development: An analysis of the antibacterial clinical development pipeline. (2019). https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf.
3. World Health Organization. Antibacterial agents in preclinical development: An open access database. (2019). https://apps.who.int/iris/bitstream/handle/10665/330290/WHO-EMP-IAU-2019.12-eng.pdf.
4. Allen, R. C., Popat, R., Diggle, S. P. & Brown, S. P. Targeting virulence: Can we make evolution-proof drugs?. Nat. Rev. Microbiol. 12, 300–308. https://doi.org/10.1038/nrmicro3232 (2014).
5. Escaich, S. Antivirulence as a new antibacterial approach for chemotherapy. Curr. Opin. Chem. Biol. 12, 400–408. https://doi.org/10.1016/j.cbpa.2008.06.022 (2008).
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献